Episode Details
Back to Episodes
Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC
Published 5 months ago
Description
CEO James Helliwell describes Eupraxia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses.